ArticleVirology2017
Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.
Article in Virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- Review
- Lymphocytic choriomeningitis arenavirus utilises intercellular connections for cell to cell spread.Scientific reports · 2024Article
- A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.NPJ vaccines · 2024Article
- Lymphocytic choriomeningitis arenavirus requires cellular COPI and AP-4 complexes for efficient virion production.Journal of virology · 2024Article
- A study on the codon usage bias of arenavirus common genes.Frontiers in microbiology · 2024Article
- Article
- Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation.Journal of virology · 2023Article
- CoDe: a web-based tool for codon deoptimization.Bioinformatics advances · 2023Article
- Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.Microbiology spectrum · 2022Article
- PROSPECTS OF LASSA FEVER CANDIDATE VACCINES.African journal of infectious diseases · 2022Article
- A comparative genomics-based study of positive strand RNA viruses emphasizing on SARS-CoV-2 utilizing dinucleotide signature, codon usage and codon context analyses.Gene reports · 2021Article
- Article
- ΦX174 Attenuation by Whole-Genome Codon Deoptimization.Genome biology and evolution · 2021Article
- Review
- Altering Compositional Properties of Viral Genomes to Design Live-Attenuated Vaccines.Frontiers in microbiology · 2021Review
- Reverse genetics approaches for the development of mammarenavirus live-attenuated vaccines.Current opinion in virology · 2020Review
- Development of Reverse Genetics for the Prototype New World Mammarenavirus Tacaribe Virus.Journal of virology · 2020Article
- A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.mBio · 2020Article
- A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.mBio · 2020Article
- Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization.NPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Several arenaviruses, chiefly Lassa (LASV) in West Africa, cause hemorrhagic fever (HF) disease in humans and pose important public health problems in their endemic regions. To date, there are no FDA-approved arenavirus vaccines and current anti-arenaviral therapy is limited to the use of ribavirin that has very limited efficacy. In this work we document that a recombinant prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) with a codon deoptimized (CD) surface glycoprotein (GP), rLCMV/CD, exhibited wild type (WT)-like growth properties in cultured cells despite barely detectable GP expression levels in rLCMV/CD-infected cells. Importantly, rLCMV/CD was highly attenuated in vivo but able to induce complete protection against a subsequent lethal challenge with rLCMV/WT. Our findings support the feasibility of implementing an arenavirus GP CD-based approach for the development of safe and effective live-attenuated vaccines (LAVs) to combat diseases caused by human pathogenic arenaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.